About InVitria
Founded in 2006, InVitria develops and manufactures recombinant, animal-origin-free proteins for cell culture, biomanufacturing and biopharmaceutical formulation applications. The company’s expertise is built around the proprietary ExpressTec® rice grain-based expression platform, which enables production of highly purified recombinant proteins without human- or animal-derived components. By providing chemically defined alternatives to serum- and blood-derived materials, InVitria supports greater consistency in cell culture workflows and helps researchers develop scalable manufacturing processes for cell and gene therapy, vaccine production, antibody manufacturing, T-cell immunotherapy and related biologics applications.
InVitria’s portfolio includes recombinant albumin, transferrin, lysozyme, lactoferrin, interleukins and cell culture supplements, together with blood-free and chemically defined media products. Key product families include Exbumin®, Optibumin®, Optiferrin®, Lacromin®, Lysobac®, Cellastim® and OptiLeukin®, which are used across upstream cell culture, bioprocess development and final formulation workflows. Manufactured using a non-mammalian recombinant expression system at an ISO 9001:2015-certified facility, these products are designed for applications requiring animal-origin-free raw materials and defined culture conditions
Europa Biosite’s subsidiaries distribute for InVitria in Belgium, Denmark, Estonia, Finland, Germany, Iceland, Ireland, Latvia, Lithuania, Luxembourg, Netherlands, Norway, Sweden and the United Kingdom.